PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

9901429-2
1105

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/47, 31/435

A1

(11) International Publication Number: **WO 98/17279**

(43) International Publication Date: 30 April 1998 (30.04.98)

(21) International Application Number: PCT/US97/19990

(22) International Filing Date: 24 October 1997 (24.10.97)

(30) Priority Data:
60/029,301 25 October 1996 (25.10.96) US
60/045,331 1 May 1997 (01.05.97) US

(71) Applicant: MINNESOTA MINING AND MANUFACTURING COMPANY [US/US]; 3M Center, P.O. Box 33427, Saint Paul, MN 55133–3427 (US).

(72) Inventors: TOMAI, Mark, A.; P.O. Box 33427, Saint Paul, MN 55133–3427 (US). HAMMERBECK, David, M.; P.O. Box 33427, Saint Paul, MN 55133–3427 (US). SWINGLE, Karl, F.; P.O. Box 33427, Saint Paul, MN 55133–3427 (US).

(74) Agents: RINGSRED, Ted, K. et al.; Minnesota Mining and Manufacturing Company, Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133–3427 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: IMMUNE RESPONSE MODIFIER COMPOUNDS FOR TREATMENT OF TH2 MEDIATED AND RELATED DISEASES

(57) Abstract

Immune response modifier compounds – imidazoquinoline amines, imidazopyridine amines, 6,7–fused cycloalkylimidazopyridine amines, and 1,2–bridged imidazoquinoline amines – are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL–4/IL–5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.